INS and hypertensive disorder: Some human studies with intervention lengths of 4–12 weeks in patients with type 2 diabetes mellitus or hypertension have reported improvements in glycosylated haemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial glucose, insulin, and C-peptide20, total cholesterol21, LDL cholesterol22, blood pressure21 for individuals with essential11 or nonresponsive23 hypertension, whilst other studies have reported no changes in glucose parameters24, 25, and unchanged LDL cholesterol25.